Returns | 1W : -5.9% , 1M : -1.5%,1Y : 92% |
LT :   |
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
BROOKS LABORATORIES LTD | -5.9% | -1.5% | 92% |
SUN PHARMACEUTICAL INDUSTRIES LTD | -1.1% | 0.1% | 30.6% |
DR REDDYS LABORATORIES LTD | -0.4% | -3.6% | 65.1% |
DIVIS LABORATORIES LTD | -0.6% | -3.9% | 94.4% |
CIPLA LTD | 0.8% | -2% | 72.3% |
BIOCON LTD | -12.3% | -18.6% | 51% |
AUROBINDO PHARMA LTD | 0.8% | 3.8% | 81.4% |
LUPIN LTD | 1.6% | 12.1% | 44.7% |
TORRENT PHARMACEUTICALS LTD | 2.1% | -3.9% | 37% |
Ratio | Value |
---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -9.87
[ Mar2020 - Standalone Results ] 1.55
P/B Calculated based on Book Value of 39.84
[ Mar2020 - Standalone Results ] 2.33
P/S Calculated based on Revenues of 65.332 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 65% 215% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |